IRD - NASDAQ
Opus Genetics, Inc.
$4.38
+9.9%Opus Genetics, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. The company offers Phentolamine Ophthalmic Solution for reversal of mydriasis, as well as is in Phase III clinical trials for presbyopia and dim light or night vision disturbances. Its lead retinal product candidate is APX3330, a small-molecule inhibitor of reduction oxidation effector factor-1 protein that has completed Phase II clinical trial for the treatment of diabetic retinopathy. The company also develops APX2009 and APX2014 that are preclinical product candidates for retina indications. The company was formerly known as Ocuphire Pharma, Inc. Opus Genetics, Inc. was founded in 2018 and is headquartered in Farmington Hills, Michigan.
At a Glance
Live Snapshotird
Net Cash Provided by Financing Activities
Last Annual Value
50.02M
3-Year CAGR
136%
5-Year CAGR
19%
10-Year CAGR
27%
Opus Genetics, Inc. Competitors Analysis of Net Cash Provided by Financing Activities
| Company | Net Cash Provided by Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
 Opus Genetics, Inc. NASDAQ:IRD | 50.02M | 77.3% | 12.6% | N/A | |
 Cognition Therapeutics, Inc. NASDAQ:CGTX | 36.57M | 100.7% | -7.2% | N/A | |
 VistaGen Therapeutics, Inc. NASDAQ:VTGN | 3.21M | N/A | -51.0% | -4.7% | |
 Acumen Pharmaceuticals, Inc. NASDAQ:ABOS | -34.00K | N/A | N/A | N/A | |
 Agenus Inc. NASDAQ:AGEN | 122.84M | 0.8% | -11.4% | N/A | |
 TuHURA Biosciences, Inc. NASDAQ:HURA | 19.93M | 95.7% | 23.1% | 8.9% | |
 Seres Therapeutics, Inc. NASDAQ:MCRB | 13.90M | -42.1% | 63.8% | 20.6% | |
 Metagenomi, Inc. Common Stock NASDAQ:MGX | -356.00K | N/A | N/A | N/A | |
 Surrozen, Inc. NASDAQ:SRZN | 85.05M | 575.4% | -7.4% | N/A | |
 Insight Molecular Diagnostics Inc. NASDAQ:IMDX | 28.07M | 32.1% | -18.6% | 11.0% | |
 Nautilus Biotechnology, Inc. NASDAQ:NAUT | 214.00K | -16.5% | -76.9% | N/A |
Opus Genetics, Inc. Fair Value Envelope
Related Guides
Continue your IRD research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.